0 Replies
Boulder, CO, September 30, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced that its Director of Biology, Eva van Rooij, Ph.D., will give a plenary lecture today at the 8th Annual Center for... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Sep 30, 2010 (BUSINESS WIRE) – RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the 9th Annual BIO Investor Forum on Wednesday, October... Contine Reading & Discuss→
0 Replies
Stories include:
Fresh off its big deal with Novartis, Quark Pharmaceuticals has announced that it plans to pursue a $20 million IPO. The company had previously backed away from a $86.25 million IPO in March 2007. Last month, Novartis agreed to pay Quark Pharmaceuticals up to $680 million for licensing... Contine Reading & Discuss→
0 Replies
Stories include:
EyeGate Pharma, which is involved in a Phase III study of its lead product, EGP-437, for the treatment of dry eye syndrome, has announced that it will collaborate with RXi Pharmaceuticals for ocular delivery of RNAi therapeutics.
The partnership will explore EyeGate's iontophoresis technology, which uses a low-level... Contine Reading & Discuss→
0 Replies
Stories include:
Bristol-Myers Squibb wasn't the only company that announced layoffs yesterday (see related story). Alnylam reported that it "will effect a corporate restructuring" with an approximate 25 percent to 30 percent reduction in overall workforce. CEO John Maraganore says the restructuring "will enable us to optimally position our company... Contine Reading & Discuss→
0 Replies
Download PDF
Santaris Pharma A/S initiates Phase 2a clinical trial with miravirsen (SPC3649) to assess safety and tolerability in treatment-naïve patients with chronic Hepatitis C
Miravirsen is the first microRNA-targeted drug to receive Investigational New Drug (IND) acceptance from FDA, paving the way to conduct Phase 2 trials for treatment... Contine Reading & Discuss→
0 Replies
Stories include:
Kalamazoo-MI-based ProNAi Therapeutics has launched Phase I clinical trials in Texas for its anti-tumor drug candidate, PNT2258, using a drug delivery technology licensed by Marina Biotech.
"We are pleased to move PNT2258 into the clinic and to be able to gain insights into the safety and promise of... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Sep 22, 2010 (BUSINESS WIRE) – RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources... Contine Reading & Discuss→
0 Replies
Stories include:
Based: Watertown, MAFounded: 2007Website: www.dicerna.comCEO: Doug Fambrough
The Scoop: Dicerna believes it has a better way to create gene-silencing molecules, making them a bit longer than the pioneers at Alnylam and Sirna/Merck in a bid to create the new-new thing in the RNAi space. And they've made some... Contine Reading & Discuss→
